Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma

Roger K. Strair, Dale Schaar, Daniel Medina, Mary B. Todd, Joseph Aisner, Robert S. DiPaola, Jacqueline Manago, Beth Knox, Amanda Jenkinson, Rachelle Senzon, Christina Baker, Liesel Dudek, Marie Ciardella, Mercy Kuriyan, Arnold Rubin, Edmund C. Lattime

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Purpose: Vaccines, cytokines, and other biologic-based therapies are being developed as antineoplastic agents. Many of these agents are designed to induce an autologous immune response directed against the malignancy. In contrast, hematopoietic stem-cell transplantation is being developed as a form of allogeneic immunotherapy. This study tests the tolerance and antineoplastic activity of sequential infusions of partially HLA-matched allogeneic blood mononuclear cells (obtained from relatives) when administered outside of the context of a hematopoietic stem-cell transplantation. The cells are irradiated to prevent graft-versus-host disease. Patients and Methods: Fifteen patients with relapsed or refractory malignancies for which no standard therapy was available were enrolled onto a clinical trial designed to assess the tolerability and antineoplastic effects of irradiated partially HLA-matched blood mononuclear cells obtained from relatives. Results: There was disease regression in three patients with metastatic renal cell carcinoma during treatment. There was disease progression in six patients with metastatic renal cell carcinoma and two patients with metastatic melanoma during treatment. There was no change in disease state in several other patients. Conclusion: Irradiated allogeneic blood mononuclear cells administered outside the context of hematopoietic stem-cell transplantation may induce disease responses in patients with relapsed or refractory malignancies. Transfusion of irradiated allogeneic blood mononuclear cells should be developed further as a novel therapeutic antineoplastic approach.

Original languageEnglish (US)
Pages (from-to)3785-3791
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number20
DOIs
StatePublished - Oct 15 2003

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma'. Together they form a unique fingerprint.

Cite this